Literature DB >> 18515327

Immune-mediated dormancy: an equilibrium with cancer.

Michele W L Teng1, Jeremy B Swann, Catherine M Koebel, Robert D Schreiber, Mark J Smyth.   

Abstract

This brief review discusses the role of the immune system in tumor development, covering a history of cancer immunity and a summary of the concept of cancer immunoediting, including its three phases: elimination, equilibrium, and escape. The latter half of this review then focuses specifically on the equilibrium phase, making note of previous work, suggesting that immunity might maintain cancer in a dormant state, and concluding with a description of a tractable mouse model unequivocally demonstrating that immunity can indeed hold preformed cancer in check. These findings form a framework for future studies aimed at validating immune-mediated cancer dormancy in humans with the hopes of devising new, immunotherapeutic strategies to treat established cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515327     DOI: 10.1189/jlb.1107774

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  108 in total

1.  Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants.

Authors:  Barbara L Andersen; Lisa M Thornton; Charles L Shapiro; William B Farrar; Bethany L Mundy; Hae-Chung Yang; William E Carson
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Authors:  Anna Sophie Berghoff; Gerda Ricken; Dorothee Wilhelm; Orsolya Rajky; Georg Widhalm; Karin Dieckmann; Peter Birner; Rupert Bartsch; Matthias Preusser
Journal:  J Neurooncol       Date:  2016-07-19       Impact factor: 4.130

3.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

4.  A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Authors:  Angela D Pardee; Dustin McCurry; Sean Alber; Peisheng Hu; Alan L Epstein; Walter J Storkus
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

5.  Visualizing cellular interactions with a generalized proximity reporter.

Authors:  Mark A Sellmyer; Laura Bronsart; Hiroshi Imoto; Christopher H Contag; Thomas J Wandless; Jennifer A Prescher
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

6.  Macrophages in skin melanoma-the key element in melanomagenesis.

Authors:  Malgorzata Pieniazek; Rafal Matkowski; Piotr Donizy
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

7.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

Review 8.  PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Authors:  Lauren C Harshman; Charles G Drake; Toni K Choueiri
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

9.  Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy.

Authors:  Kathleen P Wilkie; Philip Hahnfeldt
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

10.  Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Authors:  Henok Eyob; Huseyin Atakan Ekiz; Yoko S Derose; Susan E Waltz; Matthew A Williams; Alana L Welm
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.